Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BHC NASDAQ:HCM NYSE:OGN NASDAQ:TBPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHCBausch Health Cos$7.27+0.3%$6.87$4.25▼$9.85$2.69B0.482.37 million shs3.07 million shsHCMHUTCHMED$17.93+9.5%$16.46$11.51▼$21.50$2.86B0.4551,431 shs92,782 shsOGNOrganon & Co.$10.65-0.1%$9.64$8.01▼$21.06$2.77B0.63.50 million shs2.70 million shsTBPHTheravance Biopharma$14.30+4.4%$12.39$7.88▼$14.55$689.95M0.05527,745 shs848,891 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHCBausch Health Cos0.00%-1.02%-3.26%+20.86%+13.86%HCMHUTCHMED0.00%+12.27%+12.98%+6.09%+6.66%OGNOrganon & Co.0.00%+2.75%+13.48%+6.23%-47.17%TBPHTheravance Biopharma0.00%+2.51%+10.51%+33.77%+76.54%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHCBausch Health Cos$7.27+0.3%$6.87$4.25▼$9.85$2.69B0.482.37 million shs3.07 million shsHCMHUTCHMED$17.93+9.5%$16.46$11.51▼$21.50$2.86B0.4551,431 shs92,782 shsOGNOrganon & Co.$10.65-0.1%$9.64$8.01▼$21.06$2.77B0.63.50 million shs2.70 million shsTBPHTheravance Biopharma$14.30+4.4%$12.39$7.88▼$14.55$689.95M0.05527,745 shs848,891 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHCBausch Health Cos0.00%-1.02%-3.26%+20.86%+13.86%HCMHUTCHMED0.00%+12.27%+12.98%+6.09%+6.66%OGNOrganon & Co.0.00%+2.75%+13.48%+6.23%-47.17%TBPHTheravance Biopharma0.00%+2.51%+10.51%+33.77%+76.54%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBHCBausch Health Cos 2.00Hold$9.0023.80% UpsideHCMHUTCHMED 2.33Hold$28.0056.16% UpsideOGNOrganon & Co. 2.80Moderate Buy$17.3362.75% UpsideTBPHTheravance Biopharma 3.60Strong Buy$23.0060.84% UpsideCurrent Analyst Ratings BreakdownLatest TBPH, HCM, BHC, and OGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/12/2025TBPHTheravance BiopharmaB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$28.009/11/2025TBPHTheravance BiopharmaB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy9/9/2025HCMHUTCHMEDZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/15/2025TBPHTheravance BiopharmaZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy8/11/2025HCMHUTCHMEDZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy7/22/2025HCMHUTCHMEDBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$27.00 ➝ $28.006/27/2025TBPHTheravance BiopharmaBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$24.00 ➝ $25.006/17/2025TBPHTheravance BiopharmaJones TradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy$24.00(Data available from 9/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBHCBausch Health Cos$9.86B0.27$7.73 per share0.94($0.89) per share-8.17HCMHUTCHMED$630.20M4.96$0.31 per share56.99$4.43 per share4.05OGNOrganon & Co.$6.28B0.44$4.93 per share2.16$1.83 per share5.82TBPHTheravance Biopharma$64.38M11.19N/AN/A$3.57 per share4.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBHCBausch Health Cos-$46M$0.2627.961.56N/A0.99%-852.36%5.25%10/29/2025 (Estimated)HCMHUTCHMED$37.73MN/A0.0012.28N/AN/AN/AN/AN/AOGNOrganon & Co.$864M$2.693.962.850.9711.15%163.88%6.99%10/30/2025 (Estimated)TBPHTheravance Biopharma-$56.42M$0.2459.5840.86N/A16.88%6.93%3.52%11/11/2025 (Estimated)Latest TBPH, HCM, BHC, and OGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025OGNOrganon & Co.$0.94$1.00+$0.06$0.56$1.55 billion$1.59 billion7/30/2025Q2 2025BHCBausch Health Cos$0.97$0.90-$0.07$0.40$2.47 billion$2.57 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBHCBausch Health CosN/AN/AN/AN/AN/AHCMHUTCHMEDN/AN/AN/AN/AN/AOGNOrganon & Co.$0.080.75%N/A2.97%N/ATBPHTheravance BiopharmaN/AN/AN/AN/AN/ALatest TBPH, HCM, BHC, and OGN DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date8/5/2025OGNOrganon & Co.quarterly$0.020.9%8/15/20258/15/20259/11/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBHCBausch Health Cos141.901.310.98HCMHUTCHMED0.054.654.51OGNOrganon & Co.11.981.651.13TBPHTheravance BiopharmaN/A6.706.70Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBHCBausch Health Cos78.65%HCMHUTCHMED8.82%OGNOrganon & Co.77.43%TBPHTheravance Biopharma99.10%Insider OwnershipCompanyInsider OwnershipBHCBausch Health Cos19.97%HCMHUTCHMED3.60%OGNOrganon & Co.1.96%TBPHTheravance Biopharma6.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBHCBausch Health Cos20,700370.35 million296.39 millionOptionableHCMHUTCHMED1,811174.42 million168.14 millionNot OptionableOGNOrganon & Co.4,000259.97 million254.87 millionNot OptionableTBPHTheravance Biopharma11050.36 million46.89 millionOptionableTBPH, HCM, BHC, and OGN HeadlinesRecent News About These CompaniesTheravance Biopharma, Inc. $TBPH Shares Sold by Jacobs Levy Equity Management Inc.2 hours ago | marketbeat.comB. Riley Begins Coverage on Theravance Biopharma (NASDAQ:TBPH)September 13 at 3:45 AM | americanbankingnews.com46,972 Shares in Theravance Biopharma, Inc. $TBPH Bought by Cubist Systematic Strategies LLCSeptember 13 at 3:24 AM | marketbeat.comB. Riley Securities Initiates Coverage of Theravance Biopharma (TBPH) with Buy RecommendationSeptember 12 at 5:46 PM | msn.comTheravance Biopharma initiated with a Buy at B. RileySeptember 12 at 12:46 PM | msn.comTheravance Bio (TBPH) Up 9.8% Since Last Earnings Report: Can It Continue?September 11 at 12:30 PM | zacks.comInvesco Ltd. Sells 23,515 Shares of Theravance Biopharma, Inc. $TBPHSeptember 10, 2025 | marketbeat.comQ3 Earnings Estimate for TBPH Issued By Zacks ResearchSeptember 7, 2025 | marketbeat.comTheravance Biopharma, Inc. $TBPH Shares Bought by PDT Partners LLCSeptember 6, 2025 | marketbeat.comResearch Analysts Set Expectations for TBPH Q3 EarningsSeptember 6, 2025 | americanbankingnews.comTheravance Biopharma (NASDAQ:TBPH) Hits New 12-Month High - Should You Buy?September 4, 2025 | marketbeat.comTheravance Biopharma to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 2, 2025 | prnewswire.comWellington Management Group LLP Sells 43,062 Shares of Theravance Biopharma, Inc. $TBPHSeptember 2, 2025 | marketbeat.comRussell Investments Group Ltd. Has $429,000 Stake in Theravance Biopharma, Inc. $TBPHSeptember 2, 2025 | marketbeat.comVanguard Group Inc. Grows Stake in Theravance Biopharma, Inc. $TBPHSeptember 1, 2025 | marketbeat.comTheravance Biopharma, Inc. $TBPH Shares Sold by Deutsche Bank AGSeptember 1, 2025 | marketbeat.comNuveen LLC Acquires Shares of 374,952 Theravance Biopharma, Inc. $TBPHAugust 30, 2025 | marketbeat.comTheravance Biopharma (NASDAQ:TBPH) Stock Price Crosses Above 50 Day Moving Average - Here's WhyAugust 28, 2025 | marketbeat.comTheravance Biopharma, Inc.: Theravance Biopharma Completes Enrollment in Pivotal Phase 3 CYPRESS Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic ...August 25, 2025 | finanznachrichten.deTheravance Biopharma Completes Enrollment in Pivotal Phase 3 CYPRESS Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension due to Multiple ...August 25, 2025 | finance.yahoo.comTheravance Biopharma completes enrollment in CYPRESS studyAugust 25, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTBPH, HCM, BHC, and OGN Company DescriptionsBausch Health Cos NYSE:BHC$7.27 +0.02 (+0.28%) Closing price 09/12/2025 03:59 PM EasternExtended Trading$7.20 -0.07 (-1.03%) As of 09/12/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.HUTCHMED NASDAQ:HCM$17.93 +1.56 (+9.53%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$17.92 -0.02 (-0.08%) As of 09/12/2025 05:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.Organon & Co. NYSE:OGN$10.65 -0.01 (-0.09%) Closing price 09/12/2025 03:59 PM EasternExtended Trading$10.68 +0.03 (+0.28%) As of 09/12/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.Theravance Biopharma NASDAQ:TBPH$14.30 +0.60 (+4.38%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$14.46 +0.16 (+1.11%) As of 09/12/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
